SingleSkin & Cosmetic

SYN-AKE 200mg

A synthetic tripeptide cosmetic derivative studied for dynamic expression lines, targeting muscle nicotinic acetylcholine receptor pathways.

Mechanism

Engineered as a synthetic mimetic of waglerin-1, it is hypothesized to reversibly antagonize muscle nicotinic acetylcholine receptors at the neuromuscular junction to attenuate local muscle contractions.

Dosing

In experimental topical formulations, researchers incorporate pure SYN-AKE starting at roughly 0.3 mg per 30 g vehicle batch to establish a 10 ppm (0.001%) baseline concentration.

Reconstitution

For topical laboratory formulation, the 200 mg powder is typically dissolved into purified aqueous cosmetic vehicles or stock solutions (e.g., 20 mL yielding 10 mg/mL) rather than bacteriostatic water for injection.

Storage

Store the lyophilized pure powder sealed in a cool, dry, and dark environment, while aqueous peptide stock solutions should be maintained refrigerated between 2°C and 8°C.

Mix & measure SYN-AKE 200mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure SYN-AKE 200mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Low Formulation Tier	0.001% (10 ppm) in base	0.3 mg per 30 g topical base
Mid Formulation Tier	0.01% (100 ppm) in base	3.0 mg per 30 g topical base
High Formulation Tier	0.04% (400 ppm) in base	12.0 mg per 30 g topical base
Commercial Direct Analogue	0.004% (40 ppm) in base	1.2 mg per 30 g topical base

Reconstitution Steps

1
Confirm the peptide gross identity against the Certificate of Analysis (CAS 823202-99-9, MW 495.6 g/mol as diacetate).
2
Prepare an aqueous stock solution by dissolving 200 mg of powder into a defined volume of sterile purified water (e.g., 20 mL to yield 10 mg/mL) to ensure accurate micro-mass transfer.
3
Formulate the target base emulsion or water-based serum maintaining a final system pH between 3.0 and 7.5.
4
Incorporate the measured aqueous peptide aliquot into the base during the final processing stage at temperatures below 40 °C.
5
Homogenize thoroughly and transfer to light-protected cosmetic research vessels.

Supplies Needed

Peptide Vial

Contains 200 mg of pure synthetic SYN-AKE powder for cosmetic formulation research

Insulin Syringes (U-100)

Not utilized for topical research; precision micropipettes are used for liquid measurement

Bacteriostatic Water

Not recommended for topical vehicles; sterile deionized water or buffered aqueous solvent is preferred

Alcohol Swabs

Employed to sanitize laboratory work surfaces and compounding equipment before preparation

Why researchers study it

Investigation of topical dynamic expression line attenuation

Evaluation of neuromuscular receptor mimicry in synthetic peptides

Computer-modeled binding against matrix metalloproteinases and SIRT1

Analysis of topical peptide vehicle stability and transdermal kinetics

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

SYN-AKE (dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic cosmetic peptide designed to emulate the neuromuscular blocking properties of waglerin-1, a bioactive toxin identified in the venom of the temple pit viper. Typically provided to researchers as a 200 mg raw lyophilized powder, it is intended strictly for topical cosmetic compounding investigations rather than systemic or parenteral administration. In experimental cosmetic chemistry, researchers distinguish between commercial pre-diluted trade solutions and raw solid peptide. The commercial trade ingredient consists of a 0.1% to 1.0% peptide aqueous solution that is traditionally incorporated at 1% to 4% into finished emulsion bases. Consequently, laboratory evaluations of pure SYN-AKE focus on finished vehicle concentrations ranging between 10 ppm and 400 ppm (0.001% to 0.04% pure peptide by weight). Scientific inquiry into SYN-AKE centers on whether this abbreviated synthetic chain preserves the neuromuscular attenuation documented in its complex parent toxin. Because empirical data in human tissue models remains limited, laboratory protocols place particular emphasis on vehicle stability, accurate micro-mass dispensing, and non-invasive profilometric surface assessment.

References

1.Tan CH et al., Sci Rep, 2017 — Venomics of Tropidolaemus wagleri identifying waglerin toxins
2.DSM Nutritional Products, Personal Care Formulation Guidelines, 2020 — Technical specifications and incorporation parameters for SYN-AKE
3.Gok B et al., J Biomol Struct Dyn, 2024 — In silico docking and in vitro antioxidant profiling of Syn-Ake peptide
4.Molles BE et al., Biochemistry, 2002 — Structural mapping of waglerin-1 affinity at the nicotinic receptor alpha-epsilon interface
5.McArdle JJ et al., J Pharmacol Exp Ther, 1999 — Selective waglerin-1 antagonism of muscle nicotinic receptor epsilon isoforms
6.Hsiao YM et al., Biochem Biophys Res Commun, 1996 — Alanine scan mapping of disulfide-loop functional residues in waglerin I
7.Molles BE et al., J Biol Chem, 2002 — Cross-species selectivity differences of waglerin-1 between rodent and human receptors
8.Gorouhi F et al., Int J Cosmet Sci, 2009 — Academic review of topical neurotransmitter-inhibiting peptides in cosmetic science